Research any topic before you write.

Find related topics. | Discover entities. | See connections. | Build a topical map.

Arketamine: Novel antidepressant, Overview & Clinical development

Arketamine (developmental code names PCN-101, HR-071603), also known as (R)-ketamine or (R)-(−)-ketamine, is the (R)-(−) enantiomer of ketamine. Similarly to racemic ketamine and esketamine, the (S)-(+) enantiomer of ketamine, arketamine is biologically active; however, it is less potent as an NMDA receptor antagonist and anesthetic and thus has never…

Language: English [EN]
Use the mouse wheel or two fingers (on touchscreens) to zoom in and out of the map.
100%
More settings
100% 100% 100% 100% 100%

Arketamine topic overview

The analysis highlights Novel antidepressant, Overview and Clinical development as prominent areas in the source structure around Arketamine.

Related topics
47
Source areas
3
Connected nodes
50
Extracted relationships
28
Concept neighborhoods
28
Bridge connections
50

What this topic covers Research coverage

Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.

Overview · 24 topics
Novel antidepressant · 16 topics
Clinical development · 7 topics

Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.

Key facts & relationships

High-confidence facts extracted from structured source data. Use them as anchors for further research.

3D model (JSmol)
Interactive image
Addiction liability
Moderate
ATC code
None
CAS Number
33643-49-1
ChemSpider
559099
CompTox Dashboard (EPA)
DTXSID2048747

Explore all related topics Closing gaps

Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.

Overview

Novel antidepressant

Clinical development

Advanced semantic analysis

Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.

How Arketamine connects Entity context

The extracted context around Arketamine shows recurring relationship patterns in the source. For example, Arketamine → As, China, HR-071603, Jiangsu Hengrui Medicine, November, PCN-101, Perception Neuroscience, United States Another extracted example is Arketamine → AU: S8 (Controlled drug), CA: Schedule I, UK: Class B / Schedule 2, UN: Unscheduled, US: Schedule III. Use these groups to spot repeated connection types before inspecting the individual relationships.

Arketamine

Top relations

related to Clinical development · 8
Arketamine → As, China, HR-071603, Jiangsu Hengrui Medicine, November, PCN-101, Perception Neuroscience, United States
Legal status · 5
Arketamine → AU: S8 (Controlled drug), CA: Schedule I, UK: Class B / Schedule 2, UN: Unscheduled, US: Schedule III
related to Novel antidepressant · 3
Arketamine → As, In, NMDA
3D model (JSmol) · 1
Arketamine → Interactive image
Addiction liability · 1
Arketamine → Moderate
ATC code · 1
Arketamine → None
CAS Number · 1
Arketamine → 33643-49-1
ChemSpider · 1
Arketamine → 559099
CompTox Dashboard (EPA) · 1
Arketamine → DTXSID2048747
Formula · 1
Arketamine → C13H16ClNO

Important terminology

Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.

Important terminology

esketamine ketamine antidepressant receptor racemic potent effects clinical affinity however nmda suggested also development enantiomer anesthetic code names pcn-101 hr-071603

Arketamine relationships Subject–Predicate–Object triples

TTTA extracted 28 structured relationships around Arketamine. Examples in this analysis include Arketamine → 3D model (JSmol) → Interactive image and Arketamine → Addiction liability → Moderate. The table shows each extracted connection, where it came from and its confidence.

SubjectPredicateObjectConfidenceSrc
Arketamine3D model (JSmol)Interactive image1.00infobox
ArketamineAddiction liabilityModerate1.00infobox
ArketamineATC codeNone1.00infobox
ArketamineCAS Number33643-49-11.00infobox
ArketamineChemSpider5590991.00infobox
ArketamineCompTox Dashboard (EPA)DTXSID20487471.00infobox
ArketamineFormulaC13H16ClNO1.00infobox
ArketamineLegal statusAU: S8 (Controlled drug)1.00infobox
ArketamineLegal statusCA: Schedule I1.00infobox
ArketamineLegal statusUK: Class B / Schedule 21.00infobox
ArketamineLegal statusUS: Schedule III1.00infobox
ArketamineLegal statusUN: Unscheduled1.00infobox
ArketamineMolar mass237.73 g·mol−11.00infobox
ArketamineOther namesPCN-101; HR-0716031.00infobox
ArketaminePubChem CID6440251.00infobox
ArketamineUNIIY2RI13H7VW1.00infobox
Arketamineis aAMPA receptor agonist.Paradoxically0.90text

Related concept clusters Concept neighborhoods

The concept neighborhoods around Arketamine bring nearby vocabulary together. In this analysis, examples include Esketamine, Effects and Antidepressant. Use the clusters to find adjacent concepts and terminology that may deserve separate research.

  • Arketamine
    • Esketamine
    • Effects
    • Antidepressant
    • Receptor
    • Ketamine
    • Clinical
    • Racemic
    • Potent
    • Affinity
    • Code
    • Development
    • Hr-071603
  • arketamine
    • Esketamine
    • Effects
    • Antidepressant
    • Receptor
    • Ketamine
    • Clinical
    • Racemic
    • Potent
    • Affinity
    • Code
    • Development
    • Hr-071603
  • esketamine
    • Potent
    • Receptor
    • Effects
    • Affinity
    • Nmda
    • Racemic
    • Ketamine
    • Antidepressant
    • Accordance
    • Anesthetic
    • Antagonist
    • Dopamine
  • nmda receptor antagonist
    • Antagonist
    • Nmda
    • Lower
    • Receptor
    • Accordance
    • Anesthetic
    • Dopamine
    • Drug
    • Enantiomer
    • Inhibitor
    • Less
    • Potency
  • antidepressant
    • Clinical
    • Arketamine
    • Effects
    • Controlled
    • Novel
    • Development
    • May
    • Esketamine
    • Receptor
    • Activity
    • Depression
    • Drug
  • nmda receptor
    • Antagonist
    • Lower
    • Receptor
    • Activity
    • Agonist
    • Accordance
    • Anesthetic
    • Dopamine
    • Drug
    • Inhibitor
    • Potency
    • Relative
  • novel antidepressant
    • Clinical
    • Arketamine
    • Controlled
    • Effects
    • Novel
    • Development
    • May
    • Pcn-101
    • Esketamine
    • Receptor
    • Activity
    • Depression
  • ketamine
    • Racemic
    • Activity
    • Anesthetic
    • Less
    • Receptor
    • Potent
    • Esketamine
    • Effects
    • Accordance
    • Agonist
    • Antagonist
    • Drug

Connections between topic areas Semantic bridges

For Arketamine, one of the stronger structural bridges in this analysis connects Arketamine with Overview. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.

Min side: 3
Arketamine — Overview · splits 26 ⟂ 25
Arketamine — Novel antidepressant · splits 34 ⟂ 17
Arketamine — Clinical development · splits 43 ⟂ 8

Map overview Semantic statistics

Arketamine

Nodes51
Edges50
Triples28
Avg. degree1.96
Density0.039216
Components1

Source & methodology

TTTA analyzes the structure around Arketamine to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Novel antidepressant, Overview & Clinical development, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.

Source: Wikipedia — Arketamine · EN edition · Analysis: TopicsToTalkAbout

For writers, content strategists, SEOs, marketers and creators — from quick topic research to advanced semantic analysis.